This reflects the frequent activation of receptor tyrosine kinases, activating mutations in PI3KCA and AKT1, as well as overexpression of AKT2 or AKT3 and inactivation of the tumor suppressor gene PTEN in breast cancer [11,12]. This evidence concerns the gene AKT1 and breast carcinoma.